PR Newswire Clinical TrialsOriginal article
Nanoscope Therapeutics to Present Long-Term MCO-010 Data at the 59th Annual Retina Society Meeting
Data ReadoutMCO-010Neutral
AI Analysis
Summary
Nanoscope Therapeutics will present 4-year long-term follow-up data from the RESTORE Phase 2b/3 trial of MCO-010 in retinitis pigmentosa patients at the 59th Annual Retina Society Meeting.
Clinical Trial Data
Phase
2b/3
Outcome Details
4-year long-term follow-up data from RESTORE Phase 2b/3 trial
Importance:5/10
Sentiment:
0.00
data presentationlong-term follow-upretinitis pigmentosaophthalmologyconference
Read the original article
Published by PR Newswire Clinical Trials on September 15, 2026 11:02 AM